Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia

Pharmacotherapy

Volumn 25, Issue 12 I, 2005, Pages 1820-1825

  Jaskiewicz, Adam D ^a   Herrington, Jon D ^a   Wong, Lucas ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Bortezomib; PCL; Plasma cell leukemia; Plasmacytoma; TLS; Tumor lysis syndrome

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CELL PROLIFERATION; CYTOGENETICS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERPHOSPHATEMIA; HYPERURICEMIA; LETHARGY; METABOLIC DISORDER; MUSCLE CRAMP; NAUSEA; PLASMA CELL LEUKEMIA; RELAPSE; RISK ASSESSMENT; TUMOR LYSIS SYNDROME; VOMITING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, PLASMACYTIC; MIDDLE AGED; PYRAZINES; TUMOR LYSIS SYNDROME;

EID: 29044443093     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.12.1820     Document Type: Article

References (34)

1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116: 546-54.
2. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995;9:206-12.
3. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000;27:322-34.
4. Fassas AB, Desikan KR, Siegel D, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 1999;105:938-41.
5. Drakos P, Bar-Ziv J, Catane R. Tumor lysis syndrome in nonhematologic malignancies: report of a case and review of the literature. Am J Clin Oncol 1994;17:502-5.
6. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187-92.
7. Gold JE, Malamud SC, LaRosa F, Osband ME. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclopliosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma. Am J Hematol 1993;44:42-7.
8. Bilgrami SF, Fallon BG. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol 1993;21:521-4.
9. Shamseddine AI, Khalil AM, Wehbeh MH. Acute tumor lysis syndrome with squamous cell carcinoma of the vulva. Gynecol Oncol 1993;51:258-60.
10. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997;103:363-7.
11. Millennium Pharmaceuticals. Velcade (bortezomib) package insert. Cambridge, MA; 2004.
12. Mchta J, Jakob C, Singha S, et al. Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma [abstr]. Blood 2003;102(suppl 2):386h.
13. Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004;130:623-5.
14. Richardson P, Hideshima T, Anderson KC. Multiple myeloma and related disorders. In: Abeloff MD, Armitage JO, Niederhuber JE, et al, eds. Clinical oncology, 3rd ed. Philadelphia: Elselvier Churchill Livingstone, 2004:2970-1.
15. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukemia. Br J Haematol 1994;88:754-9.
16. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987;83:1062-8.
17. Demirkari F, Özsan GH, Özsan MA, Vural F, Çabuk M, Ündar B. Plasma cell leukemia: A report of 5 cases and review of the literature. Turk J Haematol 2001;18:275-9.
18. Fleming DR, Doukas MA. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma 1992;8:315-18.
19. Reid-Finlay M, Kaplow R. Leukemia and bone marrow transplantation. In: Schell HM, Puntillo K, eds. Critical care nursing secrets. Philadelphia: Hanley & Belfus, 2001:209-15.
20. Kjellstrand CM, Campbell DC, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974;133:349-59.
21. Tsokos GC, Balow JE, Speigel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine 1981;60:218-29.
22. Veenstra J, Krediet RT, Somers R, Arisz L. Tumour lysis syndrome and acute renal failure in Burkitrs lymphoma: description of 2 cases and a review of the literature on prevention and management. Neth J Med 1994;45:211-16.
23. Hussein AM, Feun LG. Tumor lysis syndrome after induction chemotherapy in small-cell carcinoma. Am J Clin Oncol 1990;13:10-13.
24. Barton JC. Tumor lysis syndrome in nonhematopoietic neoplasms. Cancer 1989;64:738-40.
25. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 1999;85:2305-14.
26. Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999;13:1249-57.
27. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002;8(4 suppl):S49-54.
28. Stinchcombe TE, Mitchell BS, Depcik-Smith N, et al. PS-341 is active in multiple myeloma: preliminary report of a phase 1 trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies [abstr]. Blood 2000;96:2219.
29. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
30. Schenkeln D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002;3:49-55.
31. Cheson BD. Hematologic malignancies: new developments and future treatments. Semin Oncol 2002;29(suppl 13):33-45.
32. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28:613-19.
33. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
34. Esparis-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005;114:665-7.